Accès gratuit
Volume 24, Janvier 2015
Page(s) S332 - S340
Section Session Thématique
Publié en ligne 12 février 2016
  • Abel JJ, Rowntree LG, Turner BB, (1990) Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. Transfus Sci 11:166–177 [PubMed] [Google Scholar]
  • Schwab PJ, Fahey JL, (1960) Treatment of Waldenstrom’s macro- globulinemia by plasmapheresis. N Engl J Med 263:574–579 [CrossRef] [PubMed] [Google Scholar]
  • Reimann PM, Mason PD, (1990) Plasmapheresis: technique and complications. Intensive Care Med 16:3–10 [CrossRef] [PubMed] [Google Scholar]
  • Reeves HM, Winters JL, (2014) The mechanisms of action of plasma exchange. Br J Haematol 164:342–351 [CrossRef] [PubMed] [Google Scholar]
  • Kaplan AA, (2013) Therapeutic plasma exchange: a technical and operational review. J Clin Apher 28:3–10 [CrossRef] [PubMed] [Google Scholar]
  • George JN, Nester CM, (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666 [CrossRef] [PubMed] [Google Scholar]
  • Schwartz J, Winters JL, Padmanabhan A, et al (2013) Guidelines on the use of therapeutic apheresis in clinical practice-evidence- based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145–284 [CrossRef] [PubMed] [Google Scholar]
  • Stegmayr B, Ptak J, Wikstrom B, et al (2008) World apheresis registry 2003–2007 data. Transfus Apher Sci 39:247–254 [CrossRef] [PubMed] [Google Scholar]
  • Malchesky PS, Koo AP, Skibinski CI, et al (2010) Apheresis technologies and clinical applications: the 2007 International Apheresis Registry. Ther Apher Dial 14:52–73 [CrossRef] [PubMed] [Google Scholar]
  • van den Berg B, Walgaard C, Drenthen J, et al (2014) Guillain- Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10:469–482 [CrossRef] [PubMed] [Google Scholar]
  • Raphael JC, Chevret S, Hughes RA, et al (2012) Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 7:CD001798 [PubMed] [Google Scholar]
  • Hughes RA, Swan AV, van Doorn PA (2012) Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 7:CD002063 [PubMed] [Google Scholar]
  • Sieb JP, (2014) Myasthenia gravis: an update for the clinician. Clin Exp Immunol 175:408–418 [CrossRef] [PubMed] [Google Scholar]
  • Gajdos P, Chevret S, Toyka V (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:CD002277 [PubMed] [Google Scholar]
  • Qureshi AI, Suri MF (2000) Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 4:280–286 [CrossRef] [PubMed] [Google Scholar]
  • Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev:CD002275 [PubMed] [Google Scholar]
  • Koller H, Kieseier BC, Jander S, et al (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356 [CrossRef] [PubMed] [Google Scholar]
  • Bright RJ, Wilkinson J, Coventry BJ (2014) Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. BMC Neurol 14:26 [CrossRef] [PubMed] [Google Scholar]
  • Eftimov F, Winer JB, Vermeulen M, et al (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 12:CD001797 [PubMed] [Google Scholar]
  • 2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst 15:185–195 [CrossRef] [PubMed] [Google Scholar]
  • Lunn MP, Nobile-Orazio E (2012) Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 5:CD002827 [PubMed] [Google Scholar]
  • Perlmutter SJ, Leitman SF, Garvey MA, et al (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive- compulsive disorder and tic disorders in childhood. Lancet 354:1153–1158 [CrossRef] [PubMed] [Google Scholar]
  • Garvey MA, Snider LA, Leitman SF, et al (2005) Treatment of Sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 20:424–429 [CrossRef] [PubMed] [Google Scholar]
  • Cortese I, Chaudhry V, So YT, et al (2011) Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76:294–300 [CrossRef] [PubMed] [Google Scholar]
  • Kurlan R, Kaplan EL (2004) The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinician. Pediatrics 113:883–886 [CrossRef] [PubMed] [Google Scholar]
  • Jayne DR, Gaskin G, Rasmussen N, et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188 [CrossRef] [PubMed] [Google Scholar]
  • Walsh M, Casian A, Flossmann O, et al (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84:397–402 [CrossRef] [PubMed] [Google Scholar]
  • Walsh M, Merkel PA, Peh CA, et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14:73 [CrossRef] [PubMed] [Google Scholar]
  • Pusey CD (2003) Anti-glomerular basement membrane disease. Kidney Int 64:1535–1550 [CrossRef] [PubMed] [Google Scholar]
  • Levy JB, Turner AN, Rees AJ, et al (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042 [CrossRef] [PubMed] [Google Scholar]
  • Klemmer PJ, Chalermskulrat W, Reif MS, et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153 [CrossRef] [PubMed] [Google Scholar]
  • Lazor R, Bigay-Game L, Cottin V, et al (2007) Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 86:181–193 [CrossRef] [PubMed] [Google Scholar]
  • Lammle B, Kremer Hovinga JA, Alberio L (2005) Thrombotic thrombocytopenic purpura. J Thromb Haemost 3:1663–1675 [CrossRef] [PubMed] [Google Scholar]
  • Scully M, Hunt BJ, Benjamin S, et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323–335 [CrossRef] [PubMed] [Google Scholar]
  • Naseer N, Aijaz A, Saleem MA, et al (2001) Ticlopidine- associated thrombotic thrombocytopenic purpura. Heart Dis 3:221–223 [CrossRef] [PubMed] [Google Scholar]
  • Zimmerhackl LB, Besbas N, Jungraithmayr T, et al (2006) Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 32:113–120 [CrossRef] [PubMed] [Google Scholar]
  • Ariceta G, Besbas N, Johnson S, et al (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696 [CrossRef] [PubMed] [Google Scholar]
  • Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012:617–625 [PubMed] [Google Scholar]
  • Stone MJ, Bogen SA (2012) Evidence-based focused review of management of hyperviscosity syndrome. Blood 119:2205–2208 [CrossRef] [PubMed] [Google Scholar]
  • Treon SP (2009) How I treat Waldenstrom macroglobulinemia. Blood 114:2375–2385 [CrossRef] [PubMed] [Google Scholar]
  • Ramos-Casals M, Stone JH, Cid MC, et al (2012) The cryoglo- bulinaemias. Lancet 379:348–360 [CrossRef] [PubMed] [Google Scholar]
  • Terrier B, Krastinova E, Marie I, et al (2012) Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 119:5996–6004 [CrossRef] [PubMed] [Google Scholar]
  • Dominguez JH, Sha E (2002) Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases. Ther Apher 6:69–76 [CrossRef] [PubMed] [Google Scholar]
  • Evans TW, Nicholls AJ, Shortland JR, et al (1984) Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange. Clin Nephrol 21:287–293 [PubMed] [Google Scholar]
  • Garonzik Wang JM, Montgomery RA, Kucirka LM, et al (2011) Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol 6:2041–2046 [CrossRef] [PubMed] [Google Scholar]
  • Lefaucheur C, Nochy D, Andrade J, et al (2009) Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9:1099–1107 [CrossRef] [PubMed] [Google Scholar]
  • Kawagishi N, Satomi S (2008) ABO-incompatible living donor liver transplantation: new insights into clinical relevance Transplantation 85:1523–1525 [CrossRef] [PubMed] [Google Scholar]
  • Chih S, Tinckam KJ, Ross HJ (2013) A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant 13:1069–1074 [CrossRef] [PubMed] [Google Scholar]
  • Otani S, Davis AK, Cantwell L, et al (2014) Evolving experience of treating antibody-mediated rejection following lung transplantation. Transpl Immunol 31:75–80 [CrossRef] [PubMed] [Google Scholar]
  • Valdivia P, Gonzalez Roncero F, Gentil MA, et al (2005) Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant. Transplant Proc 37:1473–1474 [CrossRef] [PubMed] [Google Scholar]
  • Cervera R, Rodriguez-Pinto I, Colafrancesco S, et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 13:699–707 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.